- Home
- IXHL vs OTLK Comparison
IXHL vs OTLK Comparison
Compare IXHL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IXHL | OTLK |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.1M | 37.5M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IXHL | OTLK |
|---|---|---|
| Price | $3.09 | $0.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 209.4K | ★ 23.5M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | N/A | ★ N/A |
| Revenue | $12,000.00 | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.16 |
| 52 Week High | $6.39 | $3.39 |
Technical Indicators
Market Signals| Indicator | IXHL | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 80.94 |
| Support Level | $0.33 | $0.79 |
| Resistance Level | $3.68 | $1.18 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 16.35 | 80.92 |
Price Performance
Historical ComparisonAbout IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.